Study links Actos with delayed dementia

Share this article:

Diabetes medication Actos could be repurposed for Alzheimer's disease. Reuters reports that a clinical trial indicates that the “cheap generic treatment” appears to be associated with delayed onset of the memory-eating disease.

Reuters notes that earlier studies indicated this may be a potential benefit, but this latest trial was a heftier effort, based on German healthcare data from 2004 through 2010 across a data set that included 146,000 patients ages 60 and older who did not initially show signs of dementia.

Researchers found that 13,841 patients eventually suffered dementia but the risk was reduced for every three months patients took Actos.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters